C4 Therapeutics Inc. (CCCC)
C4 Therapeutics Statistics
Share Statistics
C4 Therapeutics has 70.99M shares outstanding. The number of shares has increased by 3.17% in one year.
Shares Outstanding | 70.99M |
Shares Change (YoY) | 3.17% |
Shares Change (QoQ) | 0.57% |
Owned by Institutions (%) | 92.49% |
Shares Floating | 56.73M |
Failed to Deliver (FTD) Shares | 100 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 9.28M, so 13.15% of the outstanding shares have been sold short.
Short Interest | 9.28M |
Short % of Shares Out | 13.15% |
Short % of Float | 16.31% |
Short Ratio (days to cover) | 4.72 |
Valuation Ratios
The PE ratio is -2.37 and the forward PE ratio is -3.24. C4 Therapeutics's PEG ratio is 0.06.
PE Ratio | -2.37 |
Forward PE | -3.24 |
PS Ratio | 7.02 |
Forward PS | 2.8 |
PB Ratio | 1.16 |
P/FCF Ratio | -3.82 |
PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for C4 Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.3.
Current Ratio | 5.71 |
Quick Ratio | 5.71 |
Debt / Equity | 0.3 |
Debt / EBITDA | -0.64 |
Debt / FCF | -1.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $323.49K |
Profits Per Employee | $-957.42K |
Employee Count | 110 |
Asset Turnover | 0.1 |
Inventory Turnover | n/a |
Taxes
Income Tax | 131K |
Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by -81.25% in the last 52 weeks. The beta is 3, so C4 Therapeutics's price volatility has been higher than the market average.
Beta | 3 |
52-Week Price Change | -81.25% |
50-Day Moving Average | 2.77 |
200-Day Moving Average | 4.66 |
Relative Strength Index (RSI) | 20.72 |
Average Volume (20 Days) | 1.51M |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of 35.58M and earned -105.32M in profits. Earnings per share was -1.52.
Revenue | 35.58M |
Gross Profit | 35.58M |
Operating Income | -119.61M |
Net Income | -105.32M |
EBITDA | -103.37M |
EBIT | -105.19M |
Earnings Per Share (EPS) | -1.52 |
Balance Sheet
The company has 55.5M in cash and 65.76M in debt, giving a net cash position of -10.26M.
Cash & Cash Equivalents | 55.5M |
Total Debt | 65.76M |
Net Cash | -10.26M |
Retained Earnings | -633.7M |
Total Assets | 349.6M |
Working Capital | 212.59M |
Cash Flow
In the last 12 months, operating cash flow was -65.16M and capital expenditures -180K, giving a free cash flow of -65.34M.
Operating Cash Flow | -65.16M |
Capital Expenditures | -180K |
Free Cash Flow | -65.34M |
FCF Per Share | -0.94 |
Margins
Gross margin is 100%, with operating and profit margins of -336.15% and -295.96%.
Gross Margin | 100% |
Operating Margin | -336.15% |
Pretax Margin | -295.6% |
Profit Margin | -295.96% |
EBITDA Margin | -290.49% |
EBIT Margin | -336.15% |
FCF Margin | -183.61% |
Dividends & Yields
CCCC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CCCC is $13, which is 802.8% higher than the current price. The consensus rating is "Buy".
Price Target | $13 |
Price Target Difference | 802.8% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Scores
Altman Z-Score | -2.24 |
Piotroski F-Score | 4 |